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Musculoskeletal TB occurred in ~3% of the estimated 8.6 million 
people who developed tuberculosis (TB) in 2012.[1] Among these, 
spinal TB was the most common orthopaedic manifestation, and 
may lead to neurological deficits in 23 - 76% of cases.[2] Timely 
and accurate diagnosis of musculoskeletal TB and initiation of the 
appropriate therapy is crucial to prevent associated morbidity.
GeneXpert MTB/RIF (Cepheid, USA) was recently introduced 
as an automated onsite nucleic acid amplification test as a fast and 
accurate alternative diagnostic test to culture for pulmonary TB. 
In a recent meta-analysis,[3] GeneXpert MTB/RIF was reported to 
have a sensitivity of 90% for Mycobacterium tuberculosis and a 94% 
sensitivity for rifampicin resistance in pulmonary TB in adults. 
In a second meta-analysis[4] of the accuracy of GeneXpert MTB/
RIF on tissue samples (other than lymph nodes), using culture as 
a reference standard, the reported pooled sensitivity was 81.2% 
(95% confidence interval (CI) 67.7 - 89.0) and specificity was 98.1% 
(95% CI 87.0 - 99.8). However, these were samples from various tissues 
and currently there are no large studies reporting on the accuracy of 
GeneXpert MTB/RIF for musculoskeletal disease. Non-automated 
nucleic acid amplification assays have reported sensitivities of 61 - 
83% for musculoskeletal TB.[5-9] 
Only a few studies have investigated GeneXpert MTB/RIF for 
musculoskeletal disease, including a case report,[10] a small study on 
71 spinal samples that we undertook,[11] and another study on 29 
spinal tissue samples.[12] GeneXpert MTB/RIF had sensitivities of 72% 
and 82% in HIV-uninfected and HIV-infected patients, respectively; 
however, the reference standard in the study[12] was based on clinical 
and radiological findings only. It was also not conducted onsite and 
the results were only available after ~6 days, compared with 27 days 
for culture tests. Another study[13] compared GeneXpert MTB/RIF 
in 60 orthopaedic fluid samples with culture and found a sensitivity 
of 63.6%. To our knowledge, there is no large study reporting on the 
accuracy of GeneXpert MTB/RIF in tissue samples, using culture as a 
reference standard and no study has assessed whether the accuracy of 
GeneXpert MTB/RIF is affected by HIV or the location of the disease, 
such as spinal compared with extraspinal disease.
We aimed to assess the accuracy of GeneXpert MTB/RIF in surgical 
biopsies of HIV-infected and HIV-uninfected adults with suspected 
musculoskeletal TB. We also compared the time to availability of 
results for GeneXpert MTB/RIF with that of culture results, and 
differences in the accuracy of spinal and extraspinal samples.  
Methods
We conducted a prospective observational study of consecutive 
patients who were >13 years of age with clinico-radiological features of 
musculoskeletal TB. The study was performed at a large tertiary-level 
hospital in South Africa (SA), in an area with one of the highest TB 
and HIV rates worldwide. All patients underwent a musculoskeletal 
tissue biopsy for suspected TB from June 2013 to March 2015 as part 
of the routine clinical workup. As per the current standard of care at 
our centre, specimens were sent for GeneXpert MTB/RIF, culture and 
histology, as these tests are all used to inform treatment decisions. 
Patients who presented at our institution with symptoms suspicious 
of TB and who had been tested with the GeneXpert, were included in 
the study. Faulty, insufficient or contaminated GeneXpert MTB/RIF 
and TB cultures were excluded. Patients who were <13 years of age 
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were also excluded from the study. Furthermore, patients who were 
not fit for surgery were excluded. TB treatment was not recorded.
TB was suspected if patients presented with a history of back pain 
for >3 months and any of the following symptoms: constitutional 
symptoms, chronic cough, elevated erythrocyte sedimentation rate, 
history of TB contact, spinal gibbus, and immune compromise or HIV. 
Radiological features for suspected TB of a joint were local osteopenia 
and erosions involving adjacent joint surfaces. Radiological red flags 
in spinal disease were loss of anterior vertebral height, paravertebral 
shadow on radiographs, shadow of a psoas abscess, adjacent vertebral 
endplate changes with preserved disc height, changes on chest 
radiographs suspicious of TB and paravertebral abscess formation 
on magnetic resonance imaging. Biopsies were performed by a 
specialised orthopaedic service at our hospital. 
Musculoskeletal tissue samples were collected surgically from 
radiographically predetermined areas of disease in an operating room 
under sterile conditions. Tissue samples were taken from synovium 
in articular biopsies, and from bone in extra-articular biopsies. Spinal 
tissue biopsies were performed by a subspecialist surgical spinal team. 
Extraspinal lesions were biopsied by a specialised orthopaedic team. 
Extraspinal biopsies were collected by open approach and dissection 
from the area of suspected disease. Collected tissue was equally 
divided and sent for culture, histology and GeneXpert MTB/RIF in 
separate containers. The exact volume of tissue was not recorded. 
Indications for open spinal biopsies included instability, neurological 
deterioration, a large abscess or airway compromise. 
Microbiology
Specimens were submitted in duplicate and in sterile saline to 
the microbiology laboratory for simultaneous processing. The first 
specimen was processed for GeneXpert MTB/RIF testing. For this, 
the tissue was crushed after adding 1 mL of sterile saline. GeneXpert 
MTB/RIF SR lysis buffer was added in a 1:3 ratio (0.5 mL of sample 
to 1.5 mL of buffer) and the specimen was vortexed initially and 
again after ten minutes. Two millilitres of the mixture were processed 
automatically and the result was recorded after ~90 minutes. The 
GeneXpert MTB/RIF tests were performed by a trained laboratory 
technician who was blinded to the results of the reference test.
The reference standard was liquid culture or histology. Culture 
tests were done on the second specimens using the automated liquid 
culture BACTEC MGIT 960 system (Becton Dickinson Diagnostic 
Systems, USA). After the addition of 1 mL saline, the entire volume 
of sample tissue was crushed with a pestle and mortar. The sample 
was subsequently incubated overnight at 37°C on 2% blood agar 
and checked for sterility. Sterile samples were processed via the 
Bactec MGIT system according to the manufacturer’s instructions; 
any growth was decontaminated by the addition of 1 mL sodium 
hydroxide/citrate and N-Acetyl-L-cysteine to a final concentration of 
1.5%. After 20 minutes, phosphate buffer was added to a final volume 
of 50 mL and centrifuged for 15 minutes at 3 000 g. The supernatant 
was decanted and an equal volume of phosphate buffer was added 
to a 0.5 mL aliquot of the supernatant before processing via the 
BACTEC MGIT 960 system. 
A culture was regarded as negative after 42 days without growth. 
A Ziehl-Neelsen (ZN) stain and a haematoxylin and eosin stain were 
conducted in the microbiology and histopathology laboratories, 
respectively. Quantification of acid-fast bacilli (AFB) was conducted 
according to the specifications from the Centers for Disease Control 
and Prevention.[14] The isolate was assessed for multidrug-resistant 
TB (MDR-TB) using the GenoType MTBDRplus or GenoType 
Mycobacterium CM lineprobe assays (Hain Lifescience, Germany). 
MDR-TB was defined as resistance to isoniazid (INH) and rifampicin. 
A trained pathologist, who was experienced in diagnosing TB, 
reviewed the histopathology slides. Clinical data, imaging and the 
GeneXpert MTB/RIF test results were available to the pathologist. 
Histological criteria for TB were caseous necrosis, epitheloid cell 
granulomas or Langerhans giant cells.
Confirmed TB was defined as a positive M. tuberculosis culture 
or positive histology. A case was considered ‘Not TB’ if culture and 
histology results were negative and if there was improvement on follow-
up without TB treatment. The diagnostic accuracy of GeneXpert MTB/
RIF was compared with liquid culture tests and histology. Standards 
for the Reporting of Diagnostic Accuracy Studies (STARD) guidelines 
were used to design our study and report the findings.[15]
The study was approved by the Human Research Ethics Committee 
of the Faculty of Health Sciences at the University of Cape Town (ref. 
no. 264/2013). 
Statistical analysis
The sensitivity, specificity and predictive values of GeneXpert MTB/
RIF, with 95% CI, were calculated using TB culture or histology as 
the reference standard. Data were analysed per sample using STATA 
13 statistical software (STATA Corp., USA). Descriptive statistics 
were used to characterise the study population; normally distributed 
continuous data were summarised by means and 95% CIs and non-
normally distributed continuous data by medians and interquartile 
range (IQR). Categorical data were summarised as proportions with 
95% CIs. Statistical tests included two-sample tests of proportions, χ2, 
Kruskal-Wallis tests and Wilcoxon rank-sum tests. All statistical tests 
were two-sided at α=0.05.
Results
A total of 207 samples were collected from 202 patients with 
suspected musculoskeletal TB; five patients had repeat biopsies. 
One sample was excluded as the culture sample was sent in formalin 
and had to be discarded; 206 samples were therefore included. The 
biopsy sites are shown in Table 1; 122 of 206 biopsies (59.2%) were 
performed for spinal TB. The remaining biopsies were for suspected 
extraspinal TB of joints or bones. Tissue samples constituted 95.1% 
(n=196) and 4.8% (n=10) were pus samples obtained via aspiration. 
The median (IQR) age of the patients was 40 (27 - 54) years; 48.3% 
(n=97) were male. In the per sample analysis, 38.5% (n=76) were 
culture-positive compared with 41.3% (n=85) GeneXpert MTB/RIF-
positive results (Table 2). 
The sensitivity of GeneXpert MTB/RIF in musculoskeletal samples 
was 92.3% (95% CI 84.8 - 96.9) and the specificity was 99.1% (95% 
CI 95.2 - 99.8) (Table 2). For culture-confirmed TB only, the sensitivity 
of GeneXpert MTB/RIF was 90.8% (95% CI 81.9 - 96.2; p=0.724), with 
a specificity of 87.7% (95% CI 80.8 - 92.8; p<0.001). All except one 
of the culture-negative, but GeneXpert MTB/RIF-positive, samples 
showed features of TB on histology.  
In 98.5% (n=203) of samples a ZN stain was available for 
quantification of AFB, 15.8% (n=32) were positive and 84.2% (n=171) 
were negative. The sensitivity, when compared with our gold standard 
was 33.7% (95% CI 24.2 - 44.3), with a specificity of 99.1% (95% CI 95.1 
- 99.9) (Table 2). GeneXpert MTB/RIF was positive at a median (IQR) 
of 1 day (1 - 1) compared with 18 days (12 - 26) for culture results 
(p<0.001). GeneXpert MTB/RIF detected 8.8% more cases than culture 
tests (84/91 (92.3%) v. 76/91 (83.5%), respectively; p=0.069).
Drug-resistant TB 
All 4 MDR-TB cases detected with the lineprobe assay were also 
identified with GeneXpert MTB/RIF. GeneXpert MTB/RIF detected 
an additional 2 patients with rifampicin resistance in which the 
856       October 2017, Vol. 107, No. 10
RESEARCH
culture results were negative (Table 2). Therefore 6.7% (6/90) 
of patients with TB had rifampicin resistance. In one case INH 
monoresistance was detected with the lineprobe assay.  
Accuracy in samples of HIV-infected and HIV-
uninfected patients
Forty-six patients (22.9%) were HIV-infected, 50.7% (n=102) of the 
patients were HIV-uninfected and 26.4% (n=53) were of unknown 
HIV status. Among the HIV-infected patients, 69.5% (32/46) had TB 
compared with 46.1% (47/102) of the HIV-uninfected patients and 
20.7% (11/55) of the patients with unknown HIV status (p<0.001) 
(Table 1). The sensitivity of the GeneXpert MTB/RIF test was 96.9% 
(95% CI 83.8 - 99.9) in HIV-infected patients and 89.6% (95% 
CI  77.3  - 96.5; p=0.225) in HIV-uninfected patients. The specificity 
was 100% (95% CI 78.5 - 100.0) for HIV-infected patients and 98.3% 
(95% CI 90.8 - 99.9; p=0.621) in HIV-uninfected individuals (Table 3).
Accuracy in spinal and extraspinal samples
The sensitivity of GeneXpert MTB/RIF for spinal biopsies was 93.8% 
(95% CI 86.0 - 97.9) with a specificity of 97.6% (95% CI 87.4 - 99.9), 
compared with extraspinal biopsies, which had a sensitivity of 81.8% 
(95% CI 48.2 - 99.7; p=0.164) and specificity of 100% (95% CI 95.1 - 
100; p=0.186) (Table 3).
Discussion
This was the first large study to show the accuracy of GeneXpert 
MTB/RIF for the diagnosis of TB in extrapulmonary tissue biopsies 
of HIV-infected and HIV-uninfected patients with suspected 
musculoskeletal TB. We found that GeneXpert MTB/RIF had high 
sensitivities and specificities for spinal and extraspinal disease and 
provided additional diagnostic yield over culture tests. We noted 
a higher accuracy than reported in a meta-analysis evaluating 
GeneXpert MTB/RIF in extrapulmonary TB not involving 
bone or joints.[4] In addition, GeneXpert MTB/RIF was more 
sensitive than non-automated nucleic acid amplification assays 
for musculoskeletal TB reported in other studies with sensitivities 
of 61 - 83%.[5-9] Reliance on culture tests may lead to delays in 
diagnosis and treatment, with resultant serious morbidity, such 
as joint destruction, or paralysis in spinal TB.[2] The results for 
GeneXpert MTB/RIF tests, including drug resistance, were available 
much faster than liquid culture test results, which enabled timely 
diagnosis and initiation of therapy. 
Table 1.  Characteristics of patient cohort (N=201) and biopsy sites (N=206)  
Overall TB CP only 
TB CN, histology 
positive Confirmed TB Not TB p-value
Patients, n (%) 201 75 (37.3) 15 (7.5) 90 (44.8) 111 (55.2)
0.001HIV status, n (%)
Infected 46 (22.9) 24 (32.0) 8 (53.3) 32 (15.9) 14 (12.6)
Uninfected 102 (50.7) 41 (54.7) 6 (40.0) 47 (23.4) 55 (49.6)
Unknown 53 (26.4) 10 (13.3) 1 (6.7) 11 (5.5) 42 (37.8)
Sex (male), n (%) 97 (48.3) 33 (44.0) 9 (60.0) 42 (20.9) 55 (49.6) 0.485
Age (years), median (IQR) 40 (27 - 54) 35 (25 - 51) 35 (24 - 52) 42 (28 - 53) 47 (28 - 57) 0.099
Biopsy sites, n (%)
Spine 122 (59.2)
Hip 10 (4.8)
Knee 30 (14.6)
Ankle and  foot 9 (4.4)
Shoulder 6 (2.9)
Elbow 5 (2.4)
Wrist/hand 3 (1.5)
Bone 20 (9.7)
Sacroiliac joint 1 (0.5)
TB = tuberculosis; CP = culture positive; CN = culture negative; IQR = interquartile range.
Table 2. Per sample comparison of the accuracy of TB culture and GeneXpert MTB/RIF tests, and agreement between GeneXpert 
MTB/RIF and culture drug-susceptibility testing for rifampicin resistance (N=206)
All samples (n/N), 
n (%) Sens (%), 95% CI Spec (%), 95% CI PPV (%), 95% CI NPV (%), 95% CI 
Xpert 85/206
(41.3%)
92.3 
(84.8 - 96.9)
99.1 
(95.2 - 99.8)
98.8 
(93.6 - 99.8)
94.2 
(88.4 - 97.6)
Agreement with rifampicin resistance testing CR CS CIC CN Total
XR 4 0 0 2 6
XS 0 64 1 13 78
XIC 0 1 0 0 1
XN 0 7 0 114 121
Total 4 72 1 129 206
Sens = sensitivity; CI = confidence interval; Spec = specificity; PPV = positive predictive value; NPV = negative predictive value; Xpert = GeneXpert MTB/RIF; CR = culture resistant;  
CS = culture sensitive; CIC = culture inconclusive, CN = culture negative; XR = Xpert resistant; XS = Xpert sensitive; XIC = Xpert inconclusive; XN = Xpert negative.
857       October 2017, Vol. 107, No. 10
RESEARCH
A further advantage of GeneXpert MTB/RIF is the ability to rapidly 
detect resistant cases. This feature is especially important in our 
setting, as SA has a large number of patients with drug-resistant 
TB.[1] A meta-analysis of GeneXpert MTB/RIF for resistance testing 
in 566 tissue samples from 13 studies reported the prevalence of 
rifampicin resistance to be 5.4%. GeneXpert MTB/RIF did not 
detect rifampicin resistance in 2 of the 41 samples.[4] We found 
4 (4.4%) patients with MDR-TB and GeneXpert MTB/RIF detected 
an additional 2 cases of rifampicin-resistant TB who were culture-
negative. Therefore, 6 patients (6.7%) had rifampicin-resistant 
TB and GeneXpert MTB/RIF detected all of these cases. The use 
of GeneXpert MTB/RIF in these cases enabled rapid initiation of 
appropriate therapy and detected 2 additional cases, which would 
have been otherwise undetected. A limitation of the GeneXpert 
MTB/RIF test is its inability to detect INH monoresistance, which 
was the case in one sample, although the treatment is identical to 
that for drug-sensitive TB in SA.[16] 
GeneXpert MTB/RIF had a similar sensitivity in samples from HIV-
infected and HIV-uninfected patients. This trend was also reported in 
another small study.[12] HIV-infected patients may be at a particular 
risk for rapid progression of disease and morbidity.[17] The GeneXpert 
MTB/RIF assay may be especially useful in such populations. 
Study limitations
A limitation of the study was that it was conducted among adult 
patients with advanced disease who required surgery at a referral 
hospital. The generalisability of these results to patients with less 
severe disease is therefore unclear; further studies of patients with 
milder forms of musculoskeletal disease should be conducted in 
peripheral hospitals. A further limitation was that the histological 
diagnosis was made by a single pathologist, who was not blinded 
to the GeneXpert MTB/RIF results. However, clear criteria for 
histopathological diagnosis were used, and the biopsies were 
consistently reviewed in a standardised way by an experienced 
pathologist. Different methods of sample collection were used, 
guided by the anatomic area as well as severity of the disease, 
which could have resulted in suboptimal sample collection. More 
aggressive (open) approaches might have resulted in a standardised 
way of surgical sample collection, although this may have resulted 
in unacceptable morbidity. A further limitation was that HIV status 
was unknown for several patients, thus reducing the sample size for 
comparison of HIV-infected and HIV-uninfected adults. However, 
these numbers were similar to reports published by the WHO on 
our region, in which 76% of TB patients knew their HIV status in 
2013.[1]
Conclusion
GeneXpert MTB/RIF is an accurate, rapid and effective test for the 
detection of TB in tissue biopsies of HIV-infected and HIV-uninfected 
individuals with musculoskeletal TB.  It should be recommended as a 
first-line investigation for these patients and a positive result should 
be regarded as microbiological confirmation of TB.
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